Drug-like property concepts in pharmaceutical design

Current Pharmaceutical Design

Volumn 15, Issue 19, 2009, Pages 2184-2194

  Di, Li ^a   Kerns, Edward H ^a   Carter, Guy T ^a  

^a PFIZER INC   (United States)

Author keywords

ADME TOX; BCRP; Metabolism; MRP2; P glycoprotein; Permeability; Solubility; Transporters

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; CYCLIN DEPENDENT KINASE 2 INHIBITOR; DRUG; EGLUMETAD; ESTRADIOL; GABAPENTIN; GABAPENTIN ENACARBIL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; TALAGLUMETAD;

BIOASSAY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME SPECIFICITY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; STRUCTURE ANALYSIS; TOXICITY TESTING;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 69249149274     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682479     Document Type: Review

References (69)

1. Ruffolo RR. Why has R&D productivity declined in the pharmaceutical industry? Expert Opin Drug Discov 2006; 1: 99-102.
2. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988; 25: 387-96.
3. Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-6.
4. Smith DA, van de Waterbeemd H, Walker DK, Eds. Pharmacokinetics and Metabolism in Drug Des, Second Edition 2006.
5. Testa B, Kraemer SD. Wunderli-Allenspach H, Folkers G, Eds. Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies 2006.
6. Kerns EH, Di L. Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization, ELSEVIER: London 2008.
7. Gad SC. Editor. Preclinical Development Handbook; ADME and Biopharmaceutical Properties. 2008.
8. Borchardt RT, Hageman MJ, Stevens JL, Kerns EH, Thakker DR. Editors. Optimizing the "Drug-Like" Properties of Leads in Drug Discovery. In: Biotechnol.: Pharm. Aspects 2006. 4 2006.
9. Kerns EH. High Throughput In Vitro ADME/Tox Profiling for Drug Discovery. Curr Drug Metab 2008; 9: 845-6.
10. Lipinski CA. Avoiding investment in doomed drugs. Curr Drug Discov 2001; 17-9.
11. Di L, Kerns E H. Solubility Issues in Early Discovery and HTS. In Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, Patrick Augustijns; M. Brewster, eds.; Springer: New York 2007; 111-36.
12. Lipinski CA. Computational and experimental approaches to avoiding solubility and oral absorption problems in early discovery. In Designing Drugs with Optimal in Vivo Activity after Oral Administration; R. Borchardt, ed.; Drew University Residential School on Medicinal Chemistry: Madison, NJ 2000.
13. Di L, Kerns E H. Biological assay challenges from compound solubility: strategies for bioassay optimization. Drug Discov Today 2006; 11: 446-51.
14. Popa-Burke IG, Issakova O, Arroway JD, Bernasconi P, Chen M, Coudurier L, et al. Streamlined system for purifying and quantifying a diverse library of compounds and the effect of compound concentration measurements on the accurate interpretation of biological assay results. Anal Chem 2004; 76: 7278-7.
15. Lipinski CA. Solubility in water and DMSO: Issues and potential solutions. Biotechnology: Pharm Aspects 2004; 1: 93-125.
16. Ku S. Wyeth First in Human Formulation Strategy. In AAPS Conference, Oral Presentation 2008.
17. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18: 113-20.
18. Ettmayer P, Amidon GL, Clement B, Testa B. Lessons Learned from Marketed and Investigational Prodrugs. J Med Chem 2004; 47: 2393-404.
19. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW. Editors. Prodrugs: Challenges and Rewards. Prodrugs: Challenges and Rewards. In: Biotechnol.: Pharm. Aspects 2007; 5(Pt.2) 2007.
20. Hall A, Billinton A, Bristow AK, Brown SH, Chowdhury A, Cutler L, et al. Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists. Bioorg Med Chem Lett 2008; 18: 4027-32.
21. Finlay MRV, Acton DG, Andrews DM, Barker AJ, Dennis M, Fisher E, et al. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorg Med Chem Lett 2008; 18: 4442-6.
22. Brouwers J, Tack J, Augustijns P. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation. Int J Pharmaceutics 2007; 336: 302-9.
23. Liu R. Editor. Water-Insoluble Drug Formulation, Second Edition 2008.
24. Williams RO III, Taft DR, McConville JT. Editors. Adv Drug Formulation Design to Optimize Therapeutic Outcomes. In: Drugs Pharm Sci 2008; 172 2008.
25. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
26. van De Waterbeemd H, Camenisch G, Folkers G, Raevsky OA. Estimation of Caco-2 Cell Permeability using Calculated Molecular Descriptors. Quantitative Structure-Activity Relationships 1996; 15: 480-90.
27. Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, et al. Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, In Press, Corrected Proof.
28. Choong IC, Serafimova I, Fan J, Stockett D, Chan E, Cheeti S, et al. A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorg Med Chem Lett 2008; 18: 5763-5
29. Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, et al. In vitro and in vivo antimalarial activity of pepti-domimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem 2004; 12: 6517-26.
30. Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion Drug Metabol Toxicol 2006; 2: 875-94.
31. Cheung M, Harris PA, Badiang JG, Peckham GE, Chamberlain SD, Alberti MJ, et al. The identification of pyrazolo1,5-apyridines as potent p38 kinase inhibitors. Bioorg Med Chem Lett 2008; 18: 5428-30.
32. Díaz N, Benvenga M, Emmerson P, Favors R, Mangold M, McKinzie J, et al. SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists. Bioorg Med Chem Lett 2005; 15: 3844-8.
33. Hussain MA, Aungst BJ, Shefter E. Prodrugs for improved oral bestradiol bioavailability. Pharm Res 1988; 5: 44-7.
34. Ayrton A, Morgan P. Role of transport proteins in drug discovery and development: A pharmaceutical perspective. Xenobiotica 2008; 38: 676-708.
35. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039
36. Katragadda S, Jain R, Kwatra D, Hariharan S, Mitra AK. Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: Interaction with the transporters on Caco-2 cells. Int J Pharmaceut 2008; 362: 93-101.
37. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: An exception or the rule? Nat Rev Drug Discov 2008; 7: 205-20
38. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, et al. Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. Mol Pharmacol 2002; 61: 729-37.
39. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax D M. Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin. J Clin Pharmacol 2008; 48: 1378-88.
40. Perkins EJ, Abraham T. Pharmacokinetics, Metabolism, and Excretion of the PepT1-Targeted Prodrug (1S,2S,5R,6S)-2-(2'S)- (2-Amino)propionylaminobicyclo3.1.0.hexen- 2,6-dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-pass Bioactivation and Dose-Linearity. Drug Metab Dispos 2007; 35:1903-9.
41. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, et al. Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344. J Pharmacol Exp Ther 2006; 316: 905-13.
42. Zhang EY, Fu DJ, Pak YA, Stewart T, Mukhopadhyay N, Wrighton SA, et al. Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: Implications for the functional role of Pro586. J Pharmacol and Experimental Therapeut 2004; 310: 437-45.
43. Zhang EY, Emerick RM, Pak YA, Wrighton SA, Hillgren KM. Comparison of Human and Monkey Peptide Transporters: PEPT1 and PEPT2. Molecular Pharmaceutics 2004; 1: 201-10.
44. Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): A potential prodrug target. Mol Pharmaceut 2006; 3: 223-30.
45. Sievanen E. Exploitation of bile acid transport systems in prodrug design. Molecules 2007; 12: 1859-89.
46. Young JD, Yao SYM, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008; 38: 995-1021.
47. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Delivery Rev 2003; 55: 3-29.
48. Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: Historical background and new research directions. Xenobiotica 2008; 38: 833-62.
49. Pedersen JM, Matsson P, Bergstroem CAS, Norinder U, Hoogstraate J, Artursson, P. Prediction and Identification of Drug Interactions with the Human ATP-Binding Cassette Transporter Multidrug-Resistance Associated Protein 2 (MRP2; ABCC2). J Medicinal Chem 2008; 51: 3275-87.
50. Krishna R, McIntosh N, Riggs KW, Mayer LD. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 1999; 5: 2939-47.
51. Cox CD, Breslin MJ, Whitman DB, Coleman PJ, Garbaccio RM, Fraley ME, et al. Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. Bioorg Med Chem Lett 2007; 17: 2697-702.
52. Ng C, Xiao YD, Lum BL, Han YH. Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2). Eur J Pharm Sci 2005; 26: 405-13.
53. Lai Y, Xing L, Poda GI, Hu Y. Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles. Drug Metab Dispos 2007; 35: 937-45.
54. Nicolle E, Boumendjel A, Macalou S, Genoux E, Ahmed-Belkacem A, Carrupt PA, et al. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev (in press).
55. Matsson P, Englund G, Ahlin G, Bergstrom CAS, Norinder U, Artursson P. A Global Drug Inhibition Pattern for the Human ATPBinding Cassette Transporter Breast Cancer Resistance Protein (ABCG2). J Pharmacol Exp Ther 2007; 323: 19-30.
56. Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005; 70: 627-39.
57. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification Analysis of P-Glycoprotein Substrate Specificity. J Drug Target 2003; 11: 391-406.
58. Hirono S, Nakagome I, Imai R, Maeda K, Kusuhara H, Sugiyama Y. Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance-Associated Protein 2 Using Ligand-Based Drug Design Techniques. Pharm Res 2005; 22: 260-9.
59. van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, van Bladeren PJ, et al. Cnubben NHP. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005; 69: 699-708.
60. Pick A, Muller H, Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 2008; 16: 8224-36.
61. Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: Analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Therapeut 2003; 28: 203-28.
62. Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006; 27: 392-400.
63. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997; 250: 130-7.
64. Ejendal KFK, Hrycyna CA. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Molecular Pharmacol 2005; 67: 902-11.
65. Clark R, Kerr ID, Callaghan R. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 2006; 149: 506-15.
66. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, et al. Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2). J Biolog Chem 2003; 278: 23538-44.
67. Allen LV. Jr. Dosage form design and development. Clin Ther 2008; 30(11): 2102-11.
68. Foti RS, Wahlstrom JL. Prediction of CYP-mediated drug interactions in vivo using in vitro data. IDrugs 2008; 11(12): 900-5.
69. Loftsson T, Brewster ME. Physicochemical properties of water and its effect on drug delivery. A commentary. Int J Pharm 2008; 354(1-2): 248-54.